Sekundärglaukome im Rahmen retinaler Erkrankungen

Zusammenfassung

Eine Vielzahl retinaler Erkrankungen kann zur Entwicklung eines Glaukoms führen. Die häufigste Form dieser Sekundärglaukome sind die Neovaskularisationsglaukome, die den Hauptteil dieser Übersicht bilden. Dabei handelt sich um ein schwerwiegendes Krankheitsbild, das in mehreren Stadien verläuft, wobei die Prognose mit zunehmendem Stadium ungünstiger und die Therapie herausfordernder wird. Neben Pathogenese und Diagnostik wird daher ein Schwerpunkt auf die Früherkennung und eine an das jeweilige Krankheitsstadium angepasste Therapie gelegt. Auch seltenere Sekundärglaukome im Rahmen intraokularer Tumoren sowie Glaukome assoziiert mit einer Netzhautablösung (Schwartz-Matsuo-Syndrom) und Glaukome, die im Spätverlauf nach unkomplizierter Vitrektomie auftreten, werden in dieser Übersicht diskutiert.

Schlüsselwörter

Sekundärglaukom - Neovaskularisationsglaukom - diabetische Retinopathie - Zentralvenenverschluss - Schwartz-Matsuo-Syndrom - Therapie

Publikationsverlauf

Eingereicht: 01. März 2022

Angenommen: 08. März 2022

Accepted Manuscript online:
14. März 2022

Artikel online veröffentlicht:
17. Mai 2022

• References/Literatur

• 1 Moshfeghi DM, Moshfeghi AA, Finger PT. Enucleation. Surv Ophthalmol 2000; 44: 277-301 DOI: 10.1016/s0039-6257(99)00112-5.
• 2 Setlur VJ, Parikh JG, Rao NA. Changing causes of enucleation over the past 60 years. Graefes Arch Clin Exp Ophthalmol 2010; 248: 593-597 DOI: 10.1007/s00417-009-1262-8.
• 3 Gong H, Ren J, Zheng B. et al. The profile of secondary glaucoma in China: a study of over 10,000 patients. J Glaucoma 2021; 30: 895-901 DOI: 10.1097/ijg.0000000000001924.
• 4 Dubey S, Jain K, Mukherjee S. et al. Current profile of secondary glaucoma in a Northern India tertiary eye care hospital. Ophthalmic Epidemiol 2019; 26: 1-8 DOI: 10.1080/09286586.2019.1574840.
• 5 Lin PA, Lee CY, Huang FC. et al. Trend of neovascular glaucoma in Taiwan: a 15-year nationwide population-based cohort study. Ophthalmic Epidemiol 2020; 27: 390-398 DOI: 10.1080/09286586.2020.1755445.
• 6 Baseline and Early Natural History Report. The Central Vein Occlusion Study. Arch Ophthalmol 1993; 111: 1087-1095 DOI: 10.1001/archopht.1993.01090080083022.
• 7 Tasman W, Magargal LE, Augsburger JJ. Effects of argon laser photocoagulation on rubeosis iridis and angle neovascularization. Ophthalmology 1980; 87: 400-402 DOI: 10.1016/s0161-6420(80)35225-1.
• 8 Damji KF, Konstas AGP, Liebmann JM. et al. Intraocular pressure following phacoemulsification in patients with and without exfoliation syndrome: a 2 year prospective study. Br J Ophthalmol 2006; 90: 1014 DOI: 10.1136/bjo.2006.091447.
• 9 Armaly MF, Baloglou PJ. Diabetes Mellitus and the Eye: I. Changes in the Anterior Segment. Arch Ophthalmol 1967; 77: 485-492 DOI: 10.1001/archopht.1967.00980020487011.
• 10 Madsen PH. Haemorrhagic glaucoma. Comparative study in diabetic and nondiabetic patients. Br J Ophthalmol 1971; 55: 444-450 DOI: 10.1136/bjo.55.7.444.
• 11 Ohrt V. The frequency of rubeosis iridis in diabetic patients. Acta Ophthalmol (Copenh) 1971; 49: 301-307 DOI: 10.1111/j.1755-3768.1971.tb00954.x.
• 12 Nielsen NV. The prevanlence of glaucoma and ocular hypertension in type 1 and 2 diabetes mellitus. An epidemiological study of diabetes mellitus on the island of Falster, Denmark. Acta Ophthalmol (Copenh) 1983; 61: 662-672 DOI: 10.1111/j.1755-3768.1983.tb04357.x.
• 13 Rudkin AK, Lee AW, Chen CS. Ocular neovascularization following central retinal artery occlusion: prevalence and timing of onset. Eur J Ophthalmol 2010; 20: 1042-1046 DOI: 10.1177/112067211002000603.
• 14 Browning DJ, Scott AQ, Peterson CB. et al. The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion. Ophthalmology 1998; 105: 776-784 DOI: 10.1016/s0161-6420(98)95014-x.
• 15 Blinder KJ, Friedman SM, Mames RN. Diabetic iris neovascularization. Am J Ophthalmol 1995; 120: 393-395 DOI: 10.1016/s0002-9394(14)72173-7.
• 16 Neupert JR, Brubaker RF, Kearns TP. et al. Rapid resolution of venous stasis retinopathy after carotid endarterectomy. Am J Ophthalmol 1976; 81: 600-602 DOI: 10.1016/0002-9394(76)90123-9.
• 17 Terelak-Borys B, Skonieczna K, Grabska-Liberek I. Ocular ischemic syndrome – a systematic review. Med Sci Monit 2012; 18: RA138-RA144 DOI: 10.12659/msm.883260.
• 18 Wand M, Dueker DK, Aiello LM. et al. Effects of panretinal photocoagulation on rubeosis iridis, angle neovascularization, and neovascular glaucoma. Am J Ophthalmol 1978; 86: 332-339 DOI: 10.1016/0002-9394(78)90235-0.
• 19 Little HL, Rosenthal AR, Dellaporta A. et al. The effect of pan-retinal photocoagulation on rubeosis iridis. Am J Ophthalmol 1976; 81: 804-809 DOI: 10.1016/0002-9394(76)90364-0.
• 20 Laatikainen L, Kohner EM, Khoury D. et al. Panretinal photocoagulation in central retinal vein occlusion: A randomised controlled clinical study. Br J Ophthalmol 1977; 61: 741-753 DOI: 10.1136/bjo.61.12.741.
• 21 Laatikainen L. Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and neovascular glaucoma. Br J Ophthalmol 1977; 61: 278-284 DOI: 10.1136/bjo.61.4.278.
• 22 Jacobson DR, Murphy RP, Rosenthal AR. The treatment of angle neovascularization with panretinal photocoagulation. Ophthalmology 1979; 86: 1270-1275 DOI: 10.1016/s0161-6420(79)35407-0.
• 23 Murphy RP, Egbert PR. Regression of iris neovascularization following panretinal photocoagulation. Arch Ophthalmol 1979; 97: 700-702 DOI: 10.1001/archopht.1979.01020010352013.
• 24 Pavan PR, Folk JC, Weingeist TA. et al. Diabetic rubeosis and panretinal photocoagulation: a prospective, controlled, masked trial using iris fluorescein angiography. Arch Ophthalmol 1983; 101: 882-884 DOI: 10.1001/archopht.1983.01040010882003.
• 25 Magargal LE, Brown GC, Augsburger JJ. et al. Efficacy of panretinal photocoagulation in preventing neovascular glaucoma following ischemic central retinal vein obstruction. Ophthalmology 1982; 89: 780-784 DOI: 10.1016/s0161-6420(82)34724-7.
• 26 Kaufman SC, Ferris FL, Swartz M. Intraocular pressure following panretinal photocoagulation for diabetic retinopathy: diabetic retinopathy report no. 11. Arch Ophthalmol 1987; 105: 807-809 DOI: 10.1001/archopht.1987.01060060093040.
• 27 Ohnishi Y, Ishibashi T, Sagawa T. Fluorescein gonioangiography in diabetic neovascularisation. Graefes Arch Clin Exp Ophthalmol 1994; 232: 199-204 DOI: 10.1007/bf00184005.
• 28 Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 2010; 21: 112-117 DOI: 10.1097/icu.0b013e3283360aad.
• 29 Yazdani S, Hendi K, Pakravan M. et al. Intravitreal bevacizumab for neovascular glaucoma. J Glaucoma 2009; 18: 632-637 DOI: 10.1097/ijg.0b013e3181997211.
• 30 Wakabayashi T, Oshima Y, Sakaguchi H. et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115: 1571-1580.e1–e3 DOI: 10.1016/j.ophtha.2008.02.026.
• 31 European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol 2021; 105 (Suppl. 01) S1-S169 DOI: 10.1136/bjophthalmol-2021-egsguidelines.
• 32 Takihara Y, Inatani M, Fukushima M. et al. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol 2009; 147: 912-918 918.e1 DOI: 10.1016/j.ajo.2008.11.015.
• 33 Shen CC, Salim S, Du H. et al. Trabeculectomy versus Ahmed Glaucoma Valve implantation in neovascular glaucoma. Clin Ophthalmol 2011; 5: 281-286 DOI: 10.2147/OPTH.S16976.
• 34 Tsai JC, Bloom PA, Franks WA. et al. Combined transscleral diode laser cyclophotocoagulation and transscleral retinal photocoagulation for refractory neovascular glaucoma. Retina 1996; 16: 164-165 DOI: 10.1097/00006982-199616020-00016.
• 35 Bloom PA, Tsai JC, Sharma K. et al. “Cyclodiode” Trans-scleral diode laser cyclophotocoagulation in the treatment of advanced refractory glaucoma. Ophthalmology 1997; 104: 1508-1520 DOI: 10.1016/s0161-6420(97)30109-2.
• 36 Ghosh S, Singh D, Ruddle JB. et al. Combined diode laser cyclophotocoagulation and intravitreal bevacizumab (Avastin) in neovascular glaucoma. Clin Exp Ophthalmol 2010; 38: 353-357 DOI: 10.1111/j.1442-9071.2010.02285.x.
• 37 Iliev ME, Gerber S. Long-term outcome of trans-scleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol 2007; 91: 1631-1635 DOI: 10.1136/bjo.2007.116533.
• 38 Murphy CC, Burnett CAM, Spry PGD. et al. A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol 2003; 87: 1252 DOI: 10.1136/bjo.87.10.1252.
• 39 Yildirim N, Yalvac IS, Sahin A. et al. A comparative study between diode laser cyclophotocoagulation and the Ahmed glaucoma valve implant in neovascular glaucoma. J Glaucoma 2009; 18: 192-196 DOI: 10.1097/ijg.0b013e31817d235c.
• 40 Strzalkowski P, Strzalkowska A, Göbel W. et al. Combined vitrectomy, near-confluent panretinal endolaser, bevacizumab and cyclophotocoagulation for neovascular glaucoma – a retrospective interventional case series. F1000Res 2020; 9: 1236 DOI: 10.12688/f1000research.26879.2.
• 41 Camp DA, Yadav P, Dalvin LA. et al. Glaucoma secondary to intraocular tumors: mechanisms and management. Curr Opin Ophthalmol 2019; 30: 71-81 DOI: 10.1097/icu.0000000000000550.
• 42 de Leon JM, Walton DS, Latina MA. et al. Glaucoma in retinoblastoma. Semin Ophthalmol 2009; 20: 217-222 DOI: 10.1080/08820530500353831.
• 43 Vempuluru VS, Jakati S, Krishnamurthy R. et al. Glaucoma as the presenting sign of intraocular tumors: beware of the masquerading sign. Int Ophthalmol 2020; 40: 1789-1795 DOI: 10.1007/s10792-020-01348-x.
• 44 Pereira PR, Odashiro AN, Filho JPS. et al. Malignancy in the blind painful eye – report of two cases and literature review. Diagn Pathol 2006; 1: 45 DOI: 10.1186/1746-1596-1-45.
• 45 Girkin CA, Goldberg I, Mansberger SL. et al. management of iris melanoma with secondary glaucoma. J Glaucoma 2002; 11: 71-74 DOI: 10.1097/00061198-200202000-00013.
• 46 Etheridge T, Larson JC, Nork TM. et al. Schwartz-Matsuo syndrome: An important cause of secondary glaucoma. Am J Ophthalmol Case Rep 2020; 17: 100586 DOI: 10.1016/j.ajoc.2020.100586.
• 47 Chang S. LXII Edward Jackson lecture: open angle glaucoma after vitrectomy. Am J Ophthalmol 2006; 141: 1033-1043 DOI: 10.1016/j.ajo.2006.02.014.
• 48 Koreen L, Yoshida N, Escariao P. et al. Incidence of, risk factors for, and combined mechanism of late-onset open-angle glaucoma after vitrectomy. Retina 2012; 32: 160-167 DOI: 10.1097/iae.0b013e318217fffb.